References:
1. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19
Genomics UK Consortium, et al. SARS-CoV-2 variant biology: immune
escape, transmission and fitness. Nat Rev Microbiol [Internet]. 2023
Jan 18 [cited 2023 Apr 22]; Available from:
https://www.nature.com/articles/s41579-022-00841-7
2. Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, et al. Delta
spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant.
bioRxiv. 2021 Sep 5;2021.08.12.456173.
3. Hachmann NP, Miller J, Collier ARY, Ventura JD, Yu J, Rowe M, et al.
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4,
and BA.5. N Engl J Med. 2022 Jul 7;387(1):86–8.
4. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et
al. Illness duration and symptom profile in symptomatic UK school-aged
children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021
Oct;5(10):708–18.
5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder
cases and a better prognosis than adults. Acta Paediatr. 2020
Jun;109(6):1088–95.
6. Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S.
Severe COVID-19, multisystem inflammatory syndrome in children, and
Kawasaki disease: immunological mechanisms, clinical manifestations and
management. Rheumatol Int. 2021 Jan;41(1):19–32.
7. Nicole Stoesser, Ayoubkhani D, Bell I, Bell JI, Newton JN, Farrar J,
et al. WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines: An
approach to optimize the global impact of COVID-19 vaccines, based on
public health goals, global and national equity, and vaccine access and
coverage scenarios (Version 21 January 2022). Nat Microbiol. 2021
Sep;6(9):1140–9.
8. Chung YS, Lee NJ, Woo SH, Kim JM, Kim HM, Jo HJ, et al. Validation of
real-time RT-PCR for detection of SARS-CoV-2 in the early stages of the
COVID-19 outbreak in the Republic of Korea. Sci Rep. 2021 Jul
20;11(1):14817.
9. Aykac K, Cura Yayla BC, Ozsurekci Y, Evren K, Oygar PD, Gurlevik SL,
et al. The association of viral load and disease severity in children
with COVID‐19. J Med Virol. 2021 May;93(5):3077–83.
10. Loacker L, Dlaska M, Griesmacher A, Anliker M. Ct values of
different SARS CoV2 variants: a single center observational study from
Innsbruck, Austria. Clinical Chemistry and Laboratory Medicine (CCLM).
2022 Sep 27;60(10):e225–7.
11. Bayhan Gİ, Özkubat Korkmaz I, Şahiner ES, Tekeli N, Akdağ AG, Uyan
Erten AZ, et al. Are SARS-CoV-2 viral loads in children lower than in
adults? J Infect. 2023 Jan;86(1):e13–4.
12. Al-Shareef AS, Shirah B, Dabroom M, Ahmed MM, Aljohani KA, Al
Dabbagh MA, et al. Cycle Threshold Value as a Predictor of Severity and
Intensive Care Unit Admission for Children Presenting to the Emergency
Department With COVID-19: A Single-Center Experience From Saudi Arabia.
Cureus. 2022 Nov 8;14(7):e26614.
13. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson
WH, et al. Rapid Generation of Neutralizing Antibody Responses in
COVID-19 Patients. Cell Rep Med. 2020 Jun 23;1(3):100040.
14. Eberhardt KA, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C,
Rybniker J, et al. RNAemia Corresponds to Disease Severity and Antibody
Response in Hospitalized COVID-19 Patients. Viruses. 2020 Sep
18;12(9):1045.
15. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et
al. Distinct antibody responses to SARS-CoV-2 in children and adults
across the COVID-19 clinical spectrum. Nat Immunol. 2021
Jan;22(1):25–31.
16. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et
al. Neutralizing antibody levels are highly predictive of immune
protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021
Jul;27(7):1205–11.
17. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of
COVID-19 Among Children in China. Pediatrics. 2020 Jun
1;145(6):e20200702.
18. Mahalingam G, Arjunan P, Periyasami Y, Dhyani AK, Devaraju N,
Rajendiran V, et al. Correlating the differences in the receptor binding
domain of SARS-CoV-2 spike variants on their interactions with human
ACE2 receptor [Internet]. Pharmacology and Toxicology; 2022 Sep
[cited 2023 Apr 21]. Available from:
http://biorxiv.org/lookup/doi/10.1101/2022.09.30.510287
19. Toh ZQ, Anderson J, Mazarakis N, Neeland M, Higgins RA, Rautenbacher
K, et al. Comparison of Seroconversion in Children and Adults With Mild
COVID-19. JAMA Netw Open. 2022 Mar 1;5(3):e221313.
20. Pierce CA, Herold KC, Herold BC, Chou J, Randolph A, Kane B, et al.
COVID-19 and children. Science. 2022 Sep 9;377(6611):1144–9.
21. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal
analysis of antibody dynamics in COVID-19 convalescents reveals
neutralizing responses up to 16 months after infection. Nat Microbiol.
2022 Feb 7;7(3):423–33.
22. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A
longitudinal study of SARS-CoV-2-infected patients reveals a high
correlation between neutralizing antibodies and COVID-19 severity. Cell
Mol Immunol. 2021 Feb;18(2):318–27.
23. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N,
et al. Protection and Waning of Natural and Hybrid Immunity to
SARS-CoV-2. N Engl J Med. 2022 Jun 9;386(23):2201–12.
24. Li B, Deng A, Li K, Hu Y, Li Z, Shi Y, et al. Viral infection and
transmission in a large, well-traced outbreak caused by the SARS-CoV-2
Delta variant. Nat Commun. 2022 Jan 24;13(1):460.
25. Molteni E, Sudre CH, Canas LDS, Bhopal SS, Hughes RC, Chen L, et al.
Illness Characteristics of COVID-19 in Children Infected with the
SARS-CoV-2 Delta Variant. Children (Basel). 2022 May 3;9(5):652.
26. Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et
al. Transmissibility of COVID-19 depends on the viral load around onset
in adult and symptomatic patients. PLoS One. 2020;15(12):e0243597.
27. Polese-Bonatto M, Sartor ITS, Varela FH, Giannini GLT, Azevedo TR,
Kern LB, et al. Children Have Similar Reverse Transcription Polymerase
Chain Reaction Cycle Threshold for Severe Acute Respiratory Syndrome
Coronavirus 2 in Comparison With Adults. Pediatr Infect Dis J. 2021
Nov;40(11):e413–7.
28. Menges D, Zens KD, Ballouz T, Caduff N, Llanas-Cornejo D, Aschmann
HE, et al. Heterogenous humoral and cellular immune responses with
distinct trajectories post-SARS-CoV-2 infection in a population-based
cohort. Nat Commun. 2022 Aug 18;13(1):4855.
29. Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al.
Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes.
Sci Rep. 2021 Feb 10;11(1):3455.
30. Anderson EM, Diorio C, Goodwin EC, McNerney KO, Weirick ME, Gouma S,
et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and
severe COVID-19 [Internet]. Infectious Diseases (except HIV/AIDS);
2020 Aug [cited 2023 Apr 24]. Available from:
http://medrxiv.org/lookup/doi/10.1101/2020.08.17.20176552
31. Sananez I, Raiden SC, Algieri SC, Uranga M, Grisolía NA, Filippo D,
et al. A poor and delayed anti-SARS-CoV2 IgG response is associated to
severe COVID-19 in children. eBioMedicine [Internet]. 2021 Oct 1
[cited 2022 Nov 9];72. Available from:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00408-4/fulltext
32. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et
al. Multisystem Inflammatory Syndrome in Children in New York State. N
Engl J Med. 2020 Jul 23;383(4):347–58.
33. Chevaisrakul P, Lumjiaktase P, Kietdumrongwong P, Chuatrisorn I,
Chatsangjaroen P, Phanuphak N. Hybrid and herd immunity 6 months after
SARS-CoV-2 exposure among individuals from a community treatment
program. Sci Rep. 2023 Jan 14;13(1):763.
34. Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et
al. Three exposures to the spike protein of SARS-CoV-2 by either
infection or vaccination elicit superior neutralizing immunity to all
variants of concern. Nat Med. 2022 Mar;28(3):496–503.